Journal of Hepatology

Journal of Hepatology

@JHepatology

Followers10K
Following1.3K

Official journal of @EASLnews Geneva/Switzerland - RT ≠ endorsement - IF: 20.582 #hepatology #medicine #liver #healthcare #liverdisease

Geneva, Switzerland
Joined on October 05, 2012
Statistics

We looked inside some of the tweets by @JHepatology and here's what we found interesting.

Inside 100 Tweets

Time between tweets:
2 hours
Average replies
0
Average retweets
5
Average likes
10
Tweets with photos
68 / 100
Tweets with videos
0 / 100
Tweets with links
0 / 100
Researchers identify a specific genetic marker associated with the severity of non-alcoholic fatty liver disease.

https://t.co/KsOETgkmAr

This project led by @jakepmann involving @uk_biobank, @PerspectumGroup and many others highlights the value of collaborative research. https://t.co/c0SGqudaQL

Researchers identify a specific genetic marker associated with the severity of non-alcoholic fatty liver disease. https://t.co/KsOETgkmAr This project led by @jakepmann involving @uk_biobank, @PerspectumGroup and many others highlights the value of collaborative research. https://t.co/c0SGqudaQL

Read the @JHepatology paper: rs641738C>T near MBOAT7 is associated with liver fat, ALT, and fibrosis in NAFLD: a meta-analysis https://t.co/Xs75WzhgSt

The Journal of Hepatology reached 10,000 followers on twitter. 🙌 A big thanks to all our followers! Stay tuned, you will continue to find the latest developments and news in #hepatology right here. #livertwitter #liverdisease https://t.co/qTIKkmq3jE

The Journal of Hepatology reached 10,000 followers on twitter. 🙌 A big thanks to all our followers! Stay tuned, you will continue to find the latest developments and news in #hepatology right here. #livertwitter #liverdisease https://t.co/qTIKkmq3jE

The final update of the @EASLnews recommendations on treatment for #hepatitisC by @JMPawlotsky is now available at https://t.co/4wx63sqhPl. https://t.co/RDOoqSCxSE

The final update of the @EASLnews recommendations on treatment for #hepatitisC by @JMPawlotsky is now available at https://t.co/4wx63sqhPl. https://t.co/RDOoqSCxSE

Overview of DNA methylation and non-DNA methylation molecular biomarkers for detection of CCA in in primary sclerosing #cholangitis patients. Read a comprehensive overview by @GuroLind & coworkers at https://t.co/rUbLAncfy2
#cholangiocarcinoma https://t.co/ORZq6obwxg

Overview of DNA methylation and non-DNA methylation molecular biomarkers for detection of CCA in in primary sclerosing #cholangitis patients. Read a comprehensive overview by @GuroLind & coworkers at https://t.co/rUbLAncfy2 #cholangiocarcinoma https://t.co/ORZq6obwxg

Check out this @JHepatology paper by Dr.Tiejun Zhang, Xingdong Chen. The #trends in #incidence of primary #liver cancer caused by specific #etiologies: Results from #GBD Global Burden of Disease Study 2016 and implications for liver cancer #prevention https://t.co/CpoVtpkRWA

How are #transplant patients, drs & centres affected by #COVID19 worldwide? #TransplantTwitter, take part in our #survey: https://t.co/gFWMsjTXpx Deadline: 2 Oct 2020. This is a joint collaboration with @ESOTtransplant @ELITA_ELTR & @_ILTS_ https://t.co/bAHRRIbGCE

How are #transplant patients, drs & centres affected by #COVID19 worldwide? #TransplantTwitter, take part in our #survey: https://t.co/gFWMsjTXpx Deadline: 2 Oct 2020. This is a joint collaboration with @ESOTtransplant @ELITA_ELTR & @_ILTS_ https://t.co/bAHRRIbGCE

The new EASL Takeaway on Viral #Hepatitis is live. Watch it here: https://t.co/nMaSEJ4cor. 3 renowned experts in viral hepatitis – Prof. Ulrich Spengler, Prof. Geoffrey Dusheiko & Dr. Tobias Böttler – recap the key developments revealed at the Digital #ILC2020. https://t.co/TIwRa8aSd1

The new EASL Takeaway on Viral #Hepatitis is live. Watch it here: https://t.co/nMaSEJ4cor. 3 renowned experts in viral hepatitis – Prof. Ulrich Spengler, Prof. Geoffrey Dusheiko & Dr. Tobias Böttler – recap the key developments revealed at the Digital #ILC2020. https://t.co/TIwRa8aSd1

Quoted @JMPawlotsky

The final update of the EASL Recommendations on Treatment of Hepatitis C is available HERE https://t.co/iLBUjcPmJC Read them, like them, use them, advertise them ! @EASLnews @AASLDtweets @APASLnews @EASLedu @EASL_ilf @EASLEUAffairs

Congratulations @JMPawlotsky and all who contributed to the updated @EASLnews recommendations on treatment for Hepatitis C. A key document as we strive to achieve the @WHO target & eliminate HCV as a major public health threat @mcolombo46 @JVLazarus @MarkThursz @franconegro57 https://t.co/BRG6Nrfyje

ILTS
3 days ago
📣 Calling transplant centres to share how they are affected by #COVID19. All transplant centres are encouraged to take part in this survey before October 2, 2020: https://t.co/2Uf3aOr5hy 
 @ESOTtransplant 
@ELITA_ELTR
@EASLedu https://t.co/UENMc8sAEz

📣 Calling transplant centres to share how they are affected by #COVID19. All transplant centres are encouraged to take part in this survey before October 2, 2020: https://t.co/2Uf3aOr5hy @ESOTtransplant @ELITA_ELTR @EASLedu https://t.co/UENMc8sAEz

Next Generation Sequencing (NGS) identified new molecular markers associated with non-cirrhotic splanchnic vein thrombosis (NC-SVT) and might be a useful tool in the diagnosis of NC-SVT. @idibaps  @hospitalclinic @CIBERehd @ValdigGroup  @jcgarciapagan 
#MolecularDiagnosis https://t.co/PNhwcjf3Jz

Next Generation Sequencing (NGS) identified new molecular markers associated with non-cirrhotic splanchnic vein thrombosis (NC-SVT) and might be a useful tool in the diagnosis of NC-SVT. @idibaps @hospitalclinic @CIBERehd @ValdigGroup @jcgarciapagan #MolecularDiagnosis https://t.co/PNhwcjf3Jz

Loss of #VEPH1 leads to aberrantly activated mTORC1 signaling in #HCC; #rapamycin (or rapalogs) may serve as an effective treatment option for patients with low VEPH1 expression. https://t.co/jhEb1JkdNV https://t.co/bFL1id6MZr

Loss of #VEPH1 leads to aberrantly activated mTORC1 signaling in #HCC; #rapamycin (or rapalogs) may serve as an effective treatment option for patients with low VEPH1 expression. https://t.co/jhEb1JkdNV https://t.co/bFL1id6MZr

#Nutrición en los pacientes con #cirrosis: lo que se debe y lo que no se debe hacer 👉 https://t.co/79QJRtHzp9 @JHepatology https://t.co/XlIR34dyYe

#Nutrición en los pacientes con #cirrosis: lo que se debe y lo que no se debe hacer 👉 https://t.co/79QJRtHzp9 @JHepatology https://t.co/XlIR34dyYe

The October issue of @JHepatology is now available online! Read it here: https://t.co/WTwVZhEhJl @EASLnews @EASLedu https://t.co/pu6jcNKufv

The October issue of @JHepatology is now available online! Read it here: https://t.co/WTwVZhEhJl @EASLnews @EASLedu https://t.co/pu6jcNKufv

Quoted @EASLnews

Calling #TransplantTwitter. We’re jointly launching a #survey on the effects of #COVID19 on #liver #transplantation worldwide. https://t.co/ussRwmMztF All #transplant centres are urged to take part! Deadline: 2 Oct 2020. @ESOTtransplant @ELITA_ELTR @_ILTS_ @EASLedu https://t.co/aiaA3ciFOr

Calling #TransplantTwitter. We’re jointly launching a #survey on the effects of #COVID19 on #liver #transplantation worldwide. https://t.co/ussRwmMztF All #transplant centres are urged to take part! Deadline: 2 Oct 2020. @ESOTtransplant @ELITA_ELTR @_ILTS_ @EASLedu https://t.co/aiaA3ciFOr

Unique opportunity for the entire international transplant community! @EASLnews @EASLedu @EASL_ilf @JHepatology @ESOTtransplant @ELITA_ELTR @_ILTS_ @my_ueg @AisfFegato @sigeitalia @ThomasBerg24 @Hainsworth_Ben https://t.co/kgMUutGkHB

Some light reading for anyone interested in Cell Therapy and Liver Disease. Our pre-proof in Journal of Hepatology https://t.co/rT4Mbb4hgN @JHepatology

Keep an eye on EASL Campus tomorrow https://t.co/ybHozOt20F. The new EASL Takeaway on Viral #Hepatitis will be launched & will recap the key developments revealed at Digital #ILC2020. @EASLedu @JHepatology https://t.co/mHNzoMU2Lm

Keep an eye on EASL Campus tomorrow https://t.co/ybHozOt20F. The new EASL Takeaway on Viral #Hepatitis will be launched & will recap the key developments revealed at Digital #ILC2020. @EASLedu @JHepatology https://t.co/mHNzoMU2Lm

Next Page